Sensus Healthcare, Inc. Stock

Equities

SRTS

US81728J1097

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-05-28 pm EDT 5-day change 1st Jan Change
5.41 USD -11.31% Intraday chart for Sensus Healthcare, Inc. -8.92% +129.24%
Sales 2024 * 30.78M Sales 2025 * 41.72M Capitalization 100M
Net income 2024 * 3M Net income 2025 * 8M EV / Sales 2024 * 3.25 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.4 x
P/E ratio 2024 *
33 x
P/E ratio 2025 *
12.7 x
Employees 35
Yield 2024 *
-
Yield 2025 *
-
Free-Float 78.28%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.04%
1 week-2.56%
Current month+62.23%
1 month+78.89%
3 months+32.90%
6 months+143.03%
Current year+158.47%
More quotes
1 week
5.76
Extreme 5.7568
6.30
1 month
3.35
Extreme 3.35
6.55
Current year
2.36
Extreme 2.3648
6.55
1 year
1.79
Extreme 1.79
6.55
3 years
1.79
Extreme 1.79
15.25
5 years
1.76
Extreme 1.7603
15.25
10 years
1.76
Extreme 1.7603
15.25
More quotes
Managers TitleAgeSince
Founder 71 10-05-06
Chief Executive Officer 71 10-05-06
Director of Finance/CFO 52 14-12-31
Members of the board TitleAgeSince
Chief Executive Officer 71 10-05-06
Director/Board Member 71 16-07-20
Director/Board Member 77 12-01-31
More insiders
Date Price Change Volume
24-05-28 5.41 -11.31% 631 041
24-05-24 6.1 +3.04% 305,337
24-05-23 5.92 +1.54% 187,836
24-05-22 5.83 -1.85% 255,910
24-05-21 5.94 -5.11% 386,867

Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT

More quotes
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The Company uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100+ offer remote diagnostics solutions, including operation tracking.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.1 USD
Average target price
9 USD
Spread / Average Target
+47.54%
Consensus